SLAM family member 7 is a protein that in humans is encoded by the SLAMF7gene.[5][6][7]
The surface antigen CD319 (SLAMF7) is a robust marker of normal plasma cells and malignant plasma cells in multiple myeloma. In contrast to CD138 (the traditional plasma cell marker), CD319/SLAMF7 is much more stable and allows robust isolation of malignant plasma cells from delayed or even cryopreserved samples.[8]
Elotuzumab is an antibody that targets this protein.
^Boles KS, Mathew PA (Feb 2001). "Molecular cloning of CS1, a novel human natural killer cell receptor belonging to the CD2 subset of the immunoglobulin superfamily". Immunogenetics. 52 (3–4): 302–7. doi:10.1007/s002510000274. PMID11220635.
Claus M, Meinke S, Bhat R, Watzl C (2007). "Regulation of NK cell activity by 2B4, NTB-A and CRACC". Frontiers in Bioscience. 13 (13): 956–65. doi:10.2741/2735. PMID17981603.
Tovar V, del Valle J, Zapater N, Martin M, Romero X, Pizcueta P, Bosch J, Terhorst C, Engel P (Sep 2002). "Mouse novel Ly9: a new member of the expanding CD150 (SLAM) family of leukocyte cell-surface receptors". Immunogenetics. 54 (6): 394–402. doi:10.1007/s00251-002-0483-3. PMID12242590.
Lee JK, Boles KS, Mathew PA (Oct 2004). "Molecular and functional characterization of a CS1 (CRACC) splice variant expressed in human NK cells that does not contain immunoreceptor tyrosine-based switch motifs". European Journal of Immunology. 34 (10): 2791–9. doi:10.1002/eji.200424917. PMID15368295.